Nuvilex Inc. (NASDAQ:PMCB) Sees Large Drop in Short Interest

Nuvilex Inc. (NASDAQ:PMCB) was the recipient of a large decline in short interest during the month of December. As of December 15th, there was short interest totaling 635,629 shares, a decline of 31.3% from the November 30th total of 925,578 shares. Based on an average daily trading volume, of 12,965,578 shares, the short-interest ratio is currently 0.0 days. Approximately 10.4% of the company’s shares are sold short. Approximately 10.4% of the company’s shares are sold short. Based on an average daily trading volume, of 12,965,578 shares, the short-interest ratio is currently 0.0 days.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (d)” rating on shares of Nuvilex in a report on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Sell”.

Nuvilex Stock Down 0.5%

Shares of PMCB traded down $0.00 during mid-day trading on Monday, hitting $0.71. 515,329 shares of the company’s stock traded hands, compared to its average volume of 879,225. Nuvilex has a 1 year low of $0.63 and a 1 year high of $1.90. The firm has a market capitalization of $7.16 million, a P/E ratio of -0.51 and a beta of 0.07. The business’s 50-day moving average price is $0.88 and its 200-day moving average price is $0.96.

Nuvilex (NASDAQ:PMCB) last released its earnings results on Thursday, December 18th. The company reported ($0.32) EPS for the quarter.

Nuvilex Company Profile

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte.